Drug news
Keyzilen (AM 101) fails Phase III TACTT2 trial in acute inner ear tinnitus.- Auris Medical
Auris Medical Holding AG announced top-line results from the Phase III TACTT2 trial with Keyzilen (AM 101) in acute inner ear tinnitus. The TACTT2 trial did not meet the two co-primary efficacy endpoints of statistically significant changes in tinnitus loudness and tinnitus burden compared to placebo. Data from the TACTT2 trial support the positive safety profile established in previous studies, and results from the second Phase III trial, TACTT3, are expected in the fourth quarter of 2016.